Clinical Trial Update: A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy. [Phase 2]

View source ↗

Summary

Phase II dose-finding study of F-627 in breast cancer patients receiving myelotoxic chemotherapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Neutropenia

Drugs mentioned

• F-627

Snippet

Sponsor: EVIVE Biotechnology | Conditions: Neutropenia | Phase 2 | Status: COMPLETED